LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
TOUR
Tuniu Corporation
There isn't enough reported data to score TOUR yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TOUR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Healthy |
TOUR's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
TOUR PE Valuation
TOUR has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TOUR Forward outlook
There aren't enough analyst estimates for TOUR to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
TOUR Earnings Per Share
TOUR and LCID do not have enough comparable growth data to identify a winner.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
TOUR has the stronger quarterly revenue trend. Revenue is up 4.1% for LCID versus up 13% for TOUR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
TOUR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $19.9M | +13% |
| Q4 2025 | $18.5M | +20% |
| Q3 2025 | $30.3M | +8.6% |
| Q2 2025 | $20.2M | +15% |
| Q1 2025 | $17.6M | +8.9% |
| Q4 2024 | $15.4M | +2.8% |
| Q3 2024 | $27.9M | +4.4% |
| Q2 2024 | $17.5M | +17% |
TOUR's revenue has grown year over year for 13 quarters in a row: $20M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2.8% | +6.4 points |
| Q4 2025 | 0.9% | +13 points |
| Q3 2025 | 6.8% | -8.8 points |
| Q2 2025 | 5.3% | -24 points |
| Q1 2025 | -9.2% | -21 points |
| Q4 2024 | -12% | +111 points |
| Q3 2024 | 16% | -2.1 points |
| Q2 2024 | 29% | +23 points |
TOUR's operating margin was −2.8% last quarter, up 6.4 points from the same quarter a year ago.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has the stronger cash trend. Its trailing FCF is down 75% versus its history, compared with TOUR at down 100%.
TOUR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | -100% |
| Q2 2024 | $0 | -100% |
| Q1 2024 | $0 | -100% |
| Q4 2023 | $0 | -100% |
| Q3 2023 | $250.5K | -44% |
TOUR's free cash flow has been positive every quarter since mid-2020: $0 over the past year, against $250,463 the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
TOUR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.3% | -88.5K shares |
| 1 year | -5.8% | -230K shares |
TOUR has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TOUR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.8x | Net Cash |
| Q4 2025 | -3.2x | Net Cash |
| Q3 2025 | -34.6x | Net Cash |
| Q2 2025 | -14.7x | Net Cash |
| Q1 2025 | -16.8x | Net Cash |
| Q4 2024 | -5.9x | Net Cash |
| Q3 2024 | -3.8x | Net Cash |
| Q2 2024 | -6.7x | Net Cash |
TOUR has more cash than debt.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
TOUR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 12.5 | Oversold |
TOUR's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
TOUR PE vs Consumer Cyclical Sector
TOUR has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
TOUR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.86 | 3.5% below |
| 20 week MA | $4.95 | 5.3% below |
| 50 week MA | $5.94 | 21% below |
| 100 week MA | $7.53 | 38% below |
| 200 week MA | $9.63 | 51% below |
TOUR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
TOUR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.5 | $19.2 | -18% |
| 2021 | $19.2 | $9.78 | -49% |
| 2022 | $9.78 | $16.7 | +71% |
| 2023 | $16.7 | $6.71 | -60% |
| 2024 | $6.71 | $9.85 | +47% |
| 2025 | $9.85 | $7.25 | -26% |
| 2026 YTD | $7.25 | $4.69 | -35% |
TOUR has the edge over LCID on returns for 2026, with the stronger performance.